Evidence map›Paper›PMID 39496730›Full record

ArticleScientific reports2024

A deep learning framework for hepatocellular carcinoma diagnosis using MS1 data.

Wei Xu, Liying Zhang, Xiaoliang Qian, Nannan Sun, Xiao Tu, Dengfeng Zhou, Xiaoping Zheng, Jia Chen, Zewen Xie, Tao He and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wei Xu *College of Basic Medical Science, Zhejiang Chinese Medical University, 548 Binwen Rd, Hangzhou, 310053, China.
Liying Zhang *SanOmics AI Co., Ltd, Lingping District, Hangzhou, 311103, China.
Xiaoliang Qian *SanOmics AI Co., Ltd, Lingping District, Hangzhou, 311103, China.
Nannan Sun *SanOmics AI Co., Ltd, Lingping District, Hangzhou, 311103, China.
Xiao TuCollege of Basic Medical Science, Zhejiang Chinese Medical University, 548 Binwen Rd, Hangzhou, 310053, China.
Dengfeng ZhouSanOmics AI Co., Ltd, Lingping District, Hangzhou, 311103, China.
Xiaoping ZhengPathology Department, Shulan (Hangzhou) Hospital, Hangzhou, China.
Jia ChenSchool of Life Sciences, Key Laboratory of Structural Biology of Zhejiang Province, Westlake University, Hangzhou, 310024, China.
Zewen XieSanOmics AI Co., Ltd, Lingping District, Hangzhou, 311103, China.
Tao HeSanOmics AI Co., Ltd, Lingping District, Hangzhou, 311103, China.
Shugang QuSanOmics AI Co., Ltd, Lingping District, Hangzhou, 311103, China.
Yinjia WangThe First People's Hospital of Kunming, Intensive Care Unit, Kunming, 650032, China. wangyinj@163.com.
Keda YangKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, China. kdyang@zjsru.edu.cn.
Kunkai SuThe First Affiliated Hospital, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310013, China. ksu@zju.edu.cn.
Shan FengSchool of Life Sciences, Key Laboratory of Structural Biology of Zhejiang Province, Westlake University, Hangzhou, 310024, China. fengshan@westlake.edu.cn.
Bin JuSanOmics AI Co., Ltd, Lingping District, Hangzhou, 311103, China. jubin@sanomics.ai.

Funding

Fundamental Research Funds for the Central Universities No. 2022ZFJH003National Key Research and Development Program of China No. 2019YFC0840600 and No. 2019YFC0840609Spring City Plan{:}the High-level Talent Promotion and Training Project of Kunming No.2022SCP002
6 · The paper itself

Abstract

Clinical proteomics analysis is of great significance for analyzing pathological mechanisms and discovering disease-related biomarkers. Using computational methods to accurately predict disease types can effectively improve patient disease diagnosis and prognosis. However, how to eliminate the errors introduced by peptide precursor identification and protein identification for pathological diagnosis remains a major unresolved issue. Here, we develop a powerful end-to-end deep learning model, termed "MS1Former", that is able to classify hepatocellular carcinoma tumors and adjacent non-tumor (normal) tissues directly using raw MS1 spectra without peptide precursor identification. Our model provides accurate discrimination of subtle m/z differences in MS1 between tumor and adjacent non-tumor tissue, as well as more general performance predictions for data-dependent acquisition, data-independent acquisition, and full-scan data. Our model achieves the best performance on multiple external validation datasets. Additionally, we perform a detailed exploration of the model's interpretability. Prospectively, we expect that the advanced end-to-end framework will be more applicable to the classification of other tumors.

Indexed as

Carcinoma, HepatocellularDeep LearningLiver NeoplasmsProteomicsBiomarkers, TumorHumansBiomarkers, Tumor

Identifiers

PMID39496730
PMCPMC11535524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.